99 terminated. 99 Phase 2, 15 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 99 | Terminated 99 |
| Phase 1 | 15 | Terminated 15 |
| Phase 3 | 8 | Terminated 8 |
Follow Bone Diseases: new trials by email Literature Review of Bone Diseases trials Research Report on Bone Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) GS3-007a dry suspension, Insulin - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Changchun GeneScience Pharmaceutical Co., Ltd. | 120 | 2025-12-19 | 2026-05-22 |
| ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2025-10-28 | 2026-08-07 |
| A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment Vosoritide Injection - Noonan Syndrome | Phase 2 | Terminated | BioMarin Pharmaceutical | 18 | 2024-11-22 | 2026-11-13 |
| Bone in CKD Alkali Response (BICARb Pilot Trial) Potassium Citrate Extended Release Oral Tablet, Placebo, Potassium Citrate and Citric Acid Oral Solution - Chronic Kidney Diseases, Bone Loss | Phase 2 / Phase 3 | Terminated | Albert Einstein College of Medicine | 6 | 2024-08-15 | 2026-07-28 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia SAR442501 - Osteochondrodysplasia | Phase 2 | Terminated | Sanofi | 16 | 2023-10-10 | 2026-06-25 |
| VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA) Dose A VTX958, Dose B VTX958, Placebo - Psoriatic Arthritis | Phase 2 | Terminated | Ventyx Biosciences, Inc | 205 | 2023-01-31 | 2024-12-27 |
| Psoriatic Arthritis Study of Izokibep Izokibep, Placebo to izokibep - Psoriatic Arthritis | Phase 2 / Phase 3 | Terminated | ACELYRIN Inc. | 351 | 2022-11-21 | 2025-05-23 |
| Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis ATI-450, Placebo Oral Tablet - Psoriatic Arthritis | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 47 | 2022-07-12 | 2024-11-27 |
| Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis Cannabis: placebo and medium THC/medium CBD - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 2 | Terminated | Brown University | 3 | 2022-05-18 | 2025-04-01 |
| Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta Setrusumab - Osteogenesis Imperfecta | Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 2 | 2022-04-28 | 2025-07-23 |
| Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA JS005, Placebo - Non-radiographic Axial Spondyloarthritis | Phase 2 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 23 | 2021-12-31 | 2026-07-21 |
| Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia Recifercept - Achondroplasia | Phase 2 | Terminated | Pfizer | 35 | 2021-12-24 | 2024-02-08 |
| Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis Bacteriophage Therapy, Placebo - Osteomyelitis, Diabetic Foot Osteomyelitis | Phase 2 | Terminated | Adaptive Phage Therapeutics, Inc. | 41 | 2021-11-24 | 2025-08-19 |
| Effect of GLP-1 Receptor Agonists on Trabecular Bone Score GLP-1 receptor agonist - Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | University of Mississippi Medical Center | 5 | 2021-11-09 | 2025-06-13 |
| The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial 5-Aminolevulinic acid Hydrochloride - Neoplasm, Skull Base Neoplasm | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2021-09-14 | 2025-07-28 |
| A Study of CC-99677 in Participants With Active Ankylosing Spondylitis CC-99677, Placebo - Spondylitis, Ankylosing | Phase 2 | Terminated | Celgene | 167 | 2021-08-25 | 2024-05-01 |
| ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis ABY-035, Placebo - Ankylosing Spondylitis | Phase 2 | Terminated | Inmagene LLC | 25 | 2021-08-24 | 2023-07-12 |
| A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia Recifercept - Achondroplasia | Phase 2 | Terminated | Pfizer | 60 | 2020-12-02 | 2024-02-15 |
| A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma Bintrafusp alfa (M7824) - Urothelial Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2020-10-26 | 2022-03-22 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
Showing 20 of 99. Sign in to see all of them.
Osteoporosis (13) · Arthritis, Psoriatic (11) · Dwarfism, Pituitary (10) · Spondylitis, Ankylosing (7) · Camurati-Engelmann Syndrome (6) · Dwarfism (6) · Acrocephalosyndactylia (5) · Arthritis (5) · Bone Neoplasms (5) · Acromegaly (4) · Bone Diseases, Metabolic (4) · Diabetes Mellitus (4) · Musculoskeletal Diseases (4) · Psoriasis (4)
Musculoskeletal Diseases (95) · Bone Diseases, Developmental (36) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (27) · Spinal Diseases (27) · Endocrine System Diseases (26) · Nutritional and Metabolic Diseases (26) · Metabolic Diseases (25) · Skin and Connective Tissue Diseases (23) · Joint Diseases (22) · Genetic Diseases, Inborn (21) · Spondylarthritis (20) · Spondylitis (20) · Nervous System Diseases (19) · Pathological Conditions, Signs and Symptoms (19)
Gemcitabine (3) · Human Growth Hormone (3) · Saline Solution (3) · Zoledronic Acid (3) · Alendronate (2) · Calcium Carbonate (2) · Denosumab (2) · Growth Hormone (2) · Growth Hormone-Releasing Hormone (2) · Irinotecan (2) · Teriparatide (2) · Vitamin D (2) · pembrolizumab (2) · pemigatinib (2) · sonidegib (2)
Pfizer (5) · National Cancer Institute (NCI) (3) · Advanced Accelerator Applications (2) · Bristol-Myers Squibb (2) · Incyte Corporation (2) · Ipsen (2) · Sanofi (2) · Versartis Inc. (2) · ACELYRIN Inc. (1) · AbbVie (1) · Aclaris Therapeutics, Inc. (1) · Adaptive Phage Therapeutics, Inc. (1) · Albert Einstein College of Medicine (1) · Alexion Pharmaceuticals, Inc. (1) · Allergan (1)
United States (74) · Spain (22) · Poland (16) · Germany (15) · Belgium (14) · Italy (13) · Australia (12) · France (12) · Canada (10) · United Kingdom (10) · Czechia (8) · Hungary (8) · China (6) · Denmark (6) · Netherlands (6)
Dariush Elahi, PhD (2) · Will Charlton, MD (2) · Aditi Mehta, DO (1) · Alfred-Marc Iloreta, MD (1) · Alfredo Addeo, MD (1) · Andrea B Apolo, M.D. (1) · Andrew Gilman, MD (1) · Andrew M Scott, MBBS (1) · Anne Lynn Chang, MD (1) · Antonio A Lazzari, MD (1)
PMID 19654233, PMID 21128258, PMID 21593114, PMID 25166719, PMID 25968622, PMID 26773108, PMID 26828618, PMID 28735378, PMID 29175429, PMID 29296761, PMID 30032191, PMID 32461347, PMID 35137002, PMID 35727196, PMID 37162744, PMID 38685585, PMID 38710951, PMID 38875119, PMID 39665575, PMID 39722695, PMID 40648907, PMID 40676732, PMID 41188357, PMID 42167889
2019 (4), 2009 (3), 2017 (3), 2023 (2), 2014 (1), 2015 (1), 2016 (1), 2018 (1), I01RX001449 (1), KL2TR003168 (1), P01AG000599 (1), P20GM130414 (1), R01DK131811 (1)